# Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

> **NCT03785106** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **The HIV Netherlands Australia Thailand Research Collaboration** · enrollment: 2500 (actual)

## Conditions studied

- HIV-infected Participants With Latent TB Infection in High TB Burden Country

## Interventions

- **DRUG:** Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
- **DRUG:** Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

## Key facts

- **NCT ID:** NCT03785106
- **Lead sponsor:** The HIV Netherlands Australia Thailand Research Collaboration
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-15
- **Primary completion:** 2038-03
- **Final completion:** 2038-03
- **Target enrollment:** 2500 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03785106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03785106, "Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03785106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*